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ABSTRACT
In an aging society, more emphasis should be placed on prevention rather than treating diseases. Alzhei-
mer’s disease is a common sickness affecting older people. It is predicted that the number of cases will 
have increased up to 131.5 million by 2050. Therefore, the efforts of the scientific community should be 
focused on finding therapeutics that could stop or delay dementia. Statins are commonly used drugs with 
interesting pleiotropic effects. Due to its effects such as lowering  cholesterol or inhibiting of inflammatory 
reaction, they give the prospect of being used in dementia therapy. To this day, numerous studies have 
been done to verify the influence of statins on pathological elements such as beta-amyloid, Tau protein, or 
inflammatory factors. Unfortunately, a large discrepancy in the results excludes the use of these drugs in 
therapy today. The aim of our work is to validate these relations and determine the mechanisms of action 
of statins on the pathophysiology of Alzheimer’s disease. Moreover, we want to point out new directions 
of research, which may not only explain the pathomechanism of dementia but also find means to stop 
this process.
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Introduction
Epidemiological studies from the mid-1990s 
suggested a link between high cholesterol and the 
increased risk of Alzheimer’s disease (AD). It was then 
suggested that statins, due to their role in reducing 
cholesterol, may prevent the occurrence of AD or 
delay its progression [1]. However, two large studies, 
PROSPER [2] and Heart protection study [3], have 
quenched the enthusiasm of scientists, suggesting 
that there is no connection between statin therapy and 
delay or cognitive degradation. To assess the effect of 
statins on Alzheimer’s disease and its markers we need 
to get back to basics. Dementia is one of the biggest 
health problems in the world. The number of patients 
can double in twenty years and reach up to 131.5 mil-
lion by 2050 [4–6]. This is a significant problem in both 
Western and Central Europe, in which older people 
begin to dominate in demography, which translates 
into an increase in the number of patients in the coming 
years [7].
The work is focused on Alzheimer’s disease, which 
accounts for 60–80% of dementia [8]. It is irreversible 
disease [4], manifested by loss of memory, speech, 
Corresponding author: 
Adam Wełniak 
Collegium Medicum, Nicolaus  
Copernicus University, Bydgoszcz, 
Poland 
e-mail: adamw96@o2.pl
Projected number of dementia cases
3 000 000
2 000 000
1 000 000
0
Germany
1585166 
1814342
525084 
654451 
Poland
2018 2025 2050 
1075099
2748178
Figure 1. Chart showing the projected increase in the 
incidence of Alzheimer’s disease in 2018, 2025 and 2050 in 
Poland and Germany [7] [no indication in the text]
and cognitive functions, progressing over the years [8]. 
Most patients have first symptoms before 65 years of 
age and fully manifest in 30–50% before 85 years of age. 
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However, only 2–10% of patients develop the disease 
earlier. The main pathological features of brain AD are 
intracellular neurofibrillary tangles of phosphorylated 
tau protein, which are believed to have a greater role in 
pathology [4, 9, 10] and supernormal extracellular ac-
cumulation of beta-amyloid protein in amyloid plaques 
[5] and loss of cholinergic neurons [8]. Changes are
correlated with synapses loss and neuronal death [11]. 
There is a reduction in cerebral blood flow compared to 
healthy people [12]. Risk factors for AD are inflamma-
tion - acute or chronic, high cholesterol, LDL and low
HDL, type II diabetes, triglycerides, docosahexaenoic
acid 22:6 (DHA), glutamine [11] and genetic mutations, 
i.e. APOE e4, PS1 and PS2 [13, 14]. Tissue changes
precede the appearance of clinical symptoms for many 
years and neuropathological changes can be found in
people who currently have no symptoms [8]. Numer-
ous works are trying to answer the question of whether
statins are suitable for Alzheimer’s therapy [15] — we
want to answer why they can be suitable.
Statins treatment
Statins, known as HMG-CoA reductase inhibitors, 
are cholesterol-lowering drugs used to reduce the risk 
of myocardial infarction. Moreover, they are one of the 
elements of chronic coronary syndrome therapy [11]. 
However, due to their pleiotropic effect, we should 
not limit their use. Experimental studies have shown 
that statins reduce Ab production, inhibit inflammatory 
reactions, protect neurons from neurotoxicity induced 
by pathological protein, and oxidative stress [8, 16]. 
We divide statins according to their properties. Hydro-
philic statins are more selective to the liver, but are less 
permeable to BBB, while lipophilic can pass to CSN. 
GEMS (Ginko Evaluation of Memory Study) showed 
that lipophilic statins are more effective [17]. There are 
also statins in the inactive lactone form as a prodrug 
that passes into the CNS by passive diffusion. Statins 
in the form of active hydroxy acids are transported to 
the CNS by OAPT transporting polypeptides [9]. High 
statin potency is associated with a greater reduction 
in dementia risk  as opposed to lower potency statins 
[5]. They are quickly eliminated from the CNS due to 
metabolic changes from CYP3A and active reverse 
clearance by P-glycoprotein [17]. It should be empha-
sized that the use of statins in the treatment of AD is not 
only based on lowering cholesterol [9]. The action of 
statins is multi-leveled, which is why we have decided 
to refresh the topic discussed for years and indicate the 
possible directions of its development for the coming 
decade. Studies have shown that statins can act pre-
ventively in Alzheimer’s neuroprotective activity, namely 
through the ability to improve blood flow, modulation 
of the immune system, reduction of oxidative damage 
[18], anti-inflammatory properties and NO production 
and, of course, lowering LDL levels [19]. The Sacra-
mento Area Latino Study on Aging (SALSA) noted in 
5-year studies in the elderly (60-year-olds and older)
and the Indianapolis-Ibadan Dementia Project study
that it was noted that people who did not use statins
had a decrease in cognitive ability faster [20]. On the
other hand, other studies show that people not taking
statins had a slower decline in cognitive function. The
following Table 1 shows examples of studies conducted 
on popular statins and their properties.
How do statins work on risk factors for 
Alzheimer’s?
Beta-amyloid and tau protein
Cerebrospinal fluid is one of the markers of patho-
logical changes in CNS diseases. Cerebrospinal fluid 
(CSF) is a plasma-like substance that fills the ventricles 
and the surroundings of the brain. It performs nutritional 
functions and is the departure place of brain metabo-
lites, hence the conclusion that biochemical changes 
in the brain are reflected in CSF. Based on the above 
sentences, it becomes clear why CNF became one 
of the examined exponents in the case of dementia 
suspected. The “amyloid hypothesis” is a theory that 
originated in 1991 that states that both familial and spo-
radic Alzheimer’s disease is caused by the toxic effects 
of amyloid overproduction and/or aggregation. Cell 
and animal studies have linked Ab production to high 
cholesterol and statin use. The effect of statins on Ab 
plaque has not been disputed since scientists proved, 
that statins bind directly to Ab protofibrils — with ator-
vastatin binding the most [21]. This was also confirmed 
by studies on animal models [22]. Studies in a mouse 
model have shown a reduction in Ab platelet formation 
in statin therapy, which may suggest a preventative 
effect of statins in AD therapy [23].
A lot of studies dedicated to biomarkers of the 
disease focus on the deposition of b-amyloid plaques, 
and a smaller part of the work is devoted to tau protein, 
which in its physiological non-phosphorylated form 
binds to microtubules in neurons and is responsible 
for their stabilization and binding of microtubules to 
neurofilaments and cellular organelles [17]. Simvastatin 
and atorvastatin reduce the amount of phosphorylated 
tau protein [24]. Among the papers on tau protein, the 
work of Robert G. and co-authors showed that patients, 
who were treated with simvastatin for 3 months at 
20 mg/day for the first 14 days and then with 40 mg/day 
noted a decrease in the concentration of this protein in 
CSF [25]. In the O. Gribrib study, simvastatin reduced 
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Table 1. Properties of popular statins and sample studies
Statins Properties and 
force [4, 5, 17]
Research Outcome
Simvastatin lipophilic, strong 
action
•	 the CLASP [60]
•	M. Sjorgen et al. [59]
•	Liu et al. [57]
•	Simvastatin does not inhibit the development of dementia
despite significant cholesterol reduction
•	Decrease of alpha-sAPP and beta-sAPP in CSF and
increase of memory capacity
•	Beneficial effect on the cognitive competence of the
hippocampal neural network in rats
Pravastatin hydrophilic, weak 
action
•	The Prospective
Study of Pravastatin
in the Eldery at Risk-
Prosper [2]
•	Decline in cardiovascular illness, but no change in dementia
Lovastatin lipophilic, weak 
action
•	Z.Zhao et al. [63]
•	A. Eskandary at al. [10]
•	 Improves learning and memory, protects neurons from
harmful factors
•	Depending on the dose, reduces the total amount of soluble
and fibrillar Ab peptides and increases the soluble APP protein
Atorvastatin lipofilic, strong 
action
•	L. Zhao et al. [30]
•	The LEAD [61]
•	J. Wang et al. [22]
•	 Improves cognitive function, protects neurons against
inflammation and neurotoxicity Ab25-35
•	No meaningful benefits; does not increase the effect of
donepezil
•	 In combination with indomethacin, reduces beta- amyloid
plaques, restores immune function and lymphocyte
expression in the brains of APP/PS1 transgenic mice
Fluvastatin lipofilic, weak 
action
•	Tahmina Nasrin Poly et
al. [19]
•	Positively affects oxidative stress and cognitive dysfun-ction in
rats
APP — Amyloid precursor protein; sAPP — soluble amyloid precursor protein; CSF — Cerebrospinal fluid; Ab — amyloid beta;  
Ab25—35 — a fragment of Amyloid b—peptide; APP/PS1 transgenic mice — double transgenic mice expressing a chimeric mouse/human; 
amyloid precursor protein and a mutant human presenilin 1
b-secretase
and g-secretse a-secretase
Cholesterol Statins 
Inflammation 
Ab APP Ab
Figure 2. Diagram showing the degradation of the amyloid 
precursor protein by physiological and pathological 
pathways. The first takes place in the presence of alpha-
secretase, and the second at beta- and gamma-secretase 
[9, 21] [no indication in the text]
the CSF level of phospho-tau-181 (p-tau181) in all 
subjects, compared to atorvastatin, which reduced its 
level in 54% of subjects. Simvastatin and atorvastatin 
did not lower CSF or F2-isoprostane levels of bamyloid 
- markers of oxidative stress [26]. Many studies note
changes in the amount of asAPP and bsApp [27], and
Ab, levels do not change. Looking at the activities of
others, annual simvastatin therapy led to a significant
increase in CSF levels of asAPP and p-tau, while other
biochemical parameters remained unchanged. Despite 
this, researchers suggest that lower levels of Ab in CSF 
do not mean less production of this amyloid, while its 
increase is deposited in senile plaques [28]. Statins can 
prevent pathological tau phosphorylation by inhibiting 
prenylation-induced activation of one or more MAPK, 
which is the signaling pathway that statins act on. 
Simvastatin and atorvastatin allow the degradation of 
Ab40 - Ab42 by expression in the extracellular space of 
astrocytes by activation of the ERK/Akt pathway [29].
Inflammatory factors
Another mechanism of the potential effectiveness 
of statin therapy is its immunomodulatory effect. The 
markers of the inflammatory response have become the 
focus of attention of researchers looking for therapeutic 
solutions for people with dementia because as you can 
see in the studies, inflammation is an important degra-
dation factor. Something that was once a breakthrough 
today is common knowledge, and the number of works 
supporting this position is growing all the time.  Look 
at the work of Kyrkanides and colleagues. In 2011, 
they observed a link between acute and chronic sys-
temic inflammation and brain pathology. He based his 
conclusions on the results of studies that showed that 
COX-1 inhibitors with anti-inflammatory effects slow 
down cognitive decline while reducing Ab platelets [22]. 
Sun and colleagues also came to the same conclusions, 
who showed that the amyloid-beta solution induces an 
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increase in TNF-alpha and IL-6 levels [16]. Moreover, 
the amyloid b peptide has been shown to increase 
microglia activation by increasing the production of 
inflammatory cytokines interleukin-1b (IL-1b), interleu-
kin-6 (IL-6) and tumor necrosis factor a (TNF-a) [30].
As the association of Alzheimer’s with inflammatory 
factors is already clear, we have looked into the thera-
peutic perspectives of statins. Liandong Zhao et al. in 
2016 using atorvastatin on mice for 18 months obtained 
very promising effects. The exact purpose of their exper-
iment was to measure the level of hs-CRP, TNF-a, MCP-
1, IL-1b and IL-6, whose initial levels in the control and 
research groups were the same. After 18 months from 
the beginning of statin therapy, inflammation markers 
were significantly reduced (p < 0.01), whereas in the 
group not treated with a statin such a decrease was not 
obtained [31]. Another study showed that treatment 
with simvastatin and atorvastatin showed a reduction 
of inflammation and memory deficits in vivo among 
APP/PS1 transgenic mice and in Ab vaccinated mice [4]. 
A few more studies known to us achieved a reduction 
of inflammatory factors by statin therapy [25, 30]. As 
for the more accurate mechanism of immunosuppres-
sion, there are some inconsistencies associated with 
the fact that the mechanism is not fully understood. It 
is assumed that statins inhibit NF-kappaB, which initi-
ates inflammatory mechanisms, additionally activating 
PPARa and PPARγ receptors, which leads to a de-
crease in the secretion of pro-inflammatory cytokines, 
CRP protein, chemokines, adhesion molecules, and 
some extracellular matrix metalloproteinases [17]. By 
measuring the inflammatory production of IL-1b and 
TNF-a in the hippocampus by immunohistochemistry 
— Western blot and RT-PCR, atorvastatin has been 
shown to protect LTP (long term potentiation) induc-
tion and spatial memory by suppressing inflammation 
induced by Ab25-35, which has been confirmed by the 
addition of corticosteroids loaded with Ab25-35 mice 
[30]. Numerous Iba-1 positive cells were observed after 
the administration of Ab25–35. Iba1 is a calcium binding 
protein and is specifically expressed in microglia in the 
brain. The administration of Ab25–35 not only increased 
the number of Iba-1 positive cells but also increased 
the levels of IL-1b mRNA and IL-1b protein. An ATV 
administration lowered the level of these components 
[5]. Ab25-35-induced ATV-inhibited inflammatory 
response occurs by reducing FPP, and the anti-in-
flammatory effect can be blocked by supplementing 
FPP (Isoprenoids, including farnesylopyrophosphate). 
The anti-inflammatory effect of statins may also result 
from a decrease in the synthesis of nonsteroidal meva-
lonate derivatives, which is a precursor of ubiquinone, 
participates in the transport of electrons in the respi-
ratory chain and performs antioxidant functions [17]. 
In one study in mice, to determine the effectiveness of 
inflammation, levels of cytokines such as IL-6, IL-1B, 
TNF-a and ACT were measured by Real-Time PCR. 
PCR results reported a decrease in cytokines in the 
hippocampus of simvastatin-treated mice relative to the 
control group [23]. On the other hand, simvastatin trials 
in people at high risk of AD after 9 months did not show 
a decrease in CRP levels [11]. Our position is supported 
by researchers observing neuropathology who believe 
that statins prevent  the progression of AD by  inhibit-
ing inflammation [32].
The metabolism of brain cholesterol
The brain contains 23% of total cholesterol [5] 
and is the richest organ in this lipid [33]. The fact that 
there is so much of it is not without significance. It is 
synthesized in de novo brain with acetyl-CoA on the 
mevalonate pathway in the endoplasmic reticulum (ER). 
It regulates key biological functions such as signal trans-
duction, myelin sheath formation and synaptogenesis 
[17]. Changing the level of membrane cholesterol may 
affect the cleavage of APP, favoring the accumulation 
of Ab [37]. Mevalonate used together with atorvastatin 
improves its effect [24]. Removal of cholesterol from 
membranes has been shown to block long-term synap-
tic excitation (LTP) in the hippocampus. Rodent study 
results show that memory impairment in LDLr –/– mice 
is associated with an increased apoptotic mechanism 
in the brain region associated with memory formation, 
but not with the accumulation of cerebral amyloid-beta 
[24]. In vivo and in vitro studies suggest that an increase 
in blood cholesterol increases the production of Ab in 
AD. CYP46A1 polymorphism (metabolizes cholesterol 
to 24-OHc) has been shown to correlate with low brain 
cholesterol and increased risk of AD [17, 34]. Hence, 
it is worth paying attention to cholesterol metabolites 
such as 24-hydroxycholesterol (24-OH) and 27-hy-
droxycholesterol (27-OH). They are brain cholesterol 
suppressors. 24-OH can cross the blood-brain barrier 
and on the periphery correlates with the level of cho-
lesterol in the brain [4], reflects the number of active 
neurons in the brain, and thus the gray matter volume 
[33, 34]. In contrast, 27-OH accelerates cognitive defi-
cits in AD in the case of hypercholesterolemia, where 
the increase in cholesterol affects the increase of its 
inflow to the brain [4]. In the autopsy of brains affected 
by dementia, 24-OH reduction and 27-OH increase can 
be seen. Zuliani et al. suggest that 24 (S)-hydroxycho-
lesterol levels may be elevated in the early stages of AD 
due to systemic inflammation [8]. It is suggested that 
24S-hydroxycholesterol (SHC) is a biochemical marker 
of neurodegenerative diseases, as it is responsible 
for the transport of cholesterol through its enzymatic 
oxidation [1, 27].
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Cholesterol binding to neurofibrillary tangles can 
be through phytillin, a protein highly expressed in ly-
sosomes of neurons with neurofibrillary degeneration 
in AD [35]. ApoE is thought to be the major carrier 
of cholesterol in the CNS. APOEe4 selectively binds 
b-amyloid peptide, modulating its aggregation and
clearance [11]. In addition to lowering Apo A-1 levels,
statin therapy lowers ApoE levels [28]. People with
the ApoE4/ApoE4 genotype treated with simvastatin
showed better ADAS-cog results than those treated
with a placebo. Cognitive functions were significantly
better during 10 years of observation, which can be
seen in the slower decline of the MMSE test [36]. Many 
studies confirm that the presence of ApoE4 increases
the risk of late-onset of AD [32]. On the other hand,
cholesterol transport for synaptogenesis and neuronal
repair is difficult in patients with this dementia with the
ApoE4 allele, so be careful with cholesterol-lowering
drugs [37]. LXR (liver X receptor) has been shown
to modulate brain cholesterol homeostasis. In AD, in
animal models, treatment with LXR receptor agonists re-
duced inflammation and cerebral amyloid deposits. LXR 
stimulation increases APOE expression, reduces Tau
protein and its hyperphosphorylation, and b-amyloid
accumulation, reduces neuronal inflammation in the
CNS [14]. Cholesterol esters (CE) induce Alzheimer’s
disease. By reducing CE, we reduce all varieties of
Tau protein. Inhibition of cholesterol esterification by
ACAT1 deletions protects against the deposition of
pathological Tau protein. In AD, the ubiquitin-protea-
some system is reduced, and it regulates the phos-
phorylation of the tau protein [24]. There is evidence
that the low cholesterol characteristic of an aging brain
also causes AD. Reducing the amount of cholesterol 
causes changes in the activity of receptors that inhibit 
e.g. GABAa and stimulate e.g. NMDA in the CNS [17].
Studies on mice with LDL receptor knockout (receptor
dysfunction characteristic of hypercholesterolemia) of
ApoB100 mice (ldlr 65 –/–) show learning problems
in tasks in which the hippocampus is used and these
problems become increasingly difficult with age [63].
Research by Hoglund and colleagues confirms that
statins reduce cholesterol synthesis in the periphery
and the CNS [28]. Atorvastatin reduces the level of
desmosterols and lathosterols [24].
Practice and theory — the assessment 
of the effectiveness of statins in tests
General score
To fully understand the results of human studies, 
we present two key methods of assessing the effective-
ness of therapy: MMSE and ADAS-COG. Mini-Mental 
State Exam (MMSE), a short screening test assessing 
cognitive function on a scale of 0 to 30, with higher re-
sults indicating better function. The second key way to 
assess progressive dementia changes is so-called the 
gold standard — the Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (ADAS-Cog) short neuro-
psychological assessment consisting of 11 questions 
to determine the cognitive state of the interlocutor. 
Although the in vitro study in animals is dominated by 
the tendency that statins reduce the risk of developing 
Alzheimer’s disease, the most common in human stud-
ies is the lack of correlation between statin therapy and 
improved results.
Many people do not support the use of statins [38], 
and some studies of cholesterol-lowering drugs show 
that they do not affect AD [12]. In the ADNI cohort da-
tabase study, researchers came to the conclusion that 
statins do not slow down the dementia process and 
although there is some relationship in such therapy in 
people with early cognitive changes, it does not reach 
value to be seen as a potential therapeutic path [39]. 
Clinical studies suggest that high doses of statins, 
although they may reduce Ab load and delay AD pro-
gression but do not prevent the onset of the disease 
[32]. What’s more, imaging studies have shown that 
Incrased
formation of
Ab from APP
Cholesterol esters≠
Ø24-OH ≠27-OH
Figure 3. Impact of changes in cholesterol derivatives 
concentration on amyloid plaque deposition [no indication 
in the text]
Table 2. Table showing how the effects of statins on Alzheimer’s disease are distributed in studies on dementia 
patients in the cited articles
Positive influence Negative influence Lack of significant influence
9, 16, 17, 25, 26, 27, 30, 32, 36, 41, 42, 44, 
45, 59
40 5, 15, 18, 28, 38, 39, 43, 46, 47, 50, 60, 61
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statins have no effect seen in neuroimaging methods 
— and such therapy can potentially be associated with 
poorer integrity of white matter in the corpus callosum 
[40]. Considering the relationship between the choice of 
statin and therapy, one study showed that no significant 
changes in cognitive functions were observed between 
the effects of lovastatin, simvastatin and placebo [4]. Of 
course, there are works supporting statins - a controlled 
study of 6431 patients with mild to moderate Alzheimer’s 
disease found that statin use was associated with slower 
AD progression [41]. In one study, the likelihood of AD 
suffering from statins decreased by 10 percent [42]. 
Studies on people using statins with heart disease and 
an APOE gene mutation showed a slower decline in 
learning ability over 6 years [43]. A recent large popu-
lation study of several thousand people in Taiwan has 
shown that statistically, patients with one of the meta-
bolic risk factors have an increased chance of devel-
oping AD or other dementias [6]. The study confirming 
this position showed that among people exposed to 
hypertension, diabetes, and hyperlipidemia the risk of 
developing dementia is higher [11]. During the ADAPT 
(Alzheimer’s disease Anti-inflammatory Prevention 
Trial) study, which examined 2068 patients for three 
years and 6992 patients during a follow-up of 9.2 years, 
a 50% decrease in risk of AD was observed [44]. One 
study showed that continuous use of statins from the 
outset was associated with a significantly reduced risk 
of incidental dementia (p = 0.0336) and a tendency 
to reduce the risk of incidental dementia (p = 0.0609) 
compared to those who have never taken statins [45].
Low test results and numerous side effects [46] such 
as diarrhea or abdominal pain often accompany statin 
treatment - hence many people are skeptical about such 
therapy. What is more, some of the medical community 
believe that it is our duty to avoid excessive unnecessary 
medication and that statin therapy brings more prob-
lems than benefits [47]. In addition, even the most die-
hard statin defenders cannot deny that the reduction in 
central nervous system (CNS) cholesterol synthesis and 
concentration can potentially disrupt the functioning 
of cholesterol-rich myelin fibers [48]. Simvastatin and 
atorvastatin cause more death of astrocytes than other 
cholesterol-lowering drugs (efavirenz) [24]. However, 
there are also works that do not share the views of 
their predecessors. According to a meta-analysis from 
2015, statins do not reveal side effects in people without 
dementia [17]. Defenders of the contribution of statins 
to neuroprotection have tried to use statins along with 
traditional Alzheimer drugs. In 2007, the effectiveness 
of galantamine, statin together with galantamine and 
statin alone was tested, as well as a placebo trial [46]. 
Although minimal changes were noted in the MMSE 
and Adas cog tests compared to the statin group and 
placebo, they were insignificant. The trial showed that 
these drugs do not exist as an additional element of 
therapy. However, there is a discrepancy in such re-
search in which one study showed that lovastatin can 
synergistically enhance the effect of donepezil, which, 
on the other hand, the authors explain, may result from 
the fact that the drugs together improve the activity of 
NMDA receptors and mask acetylcholine by increasing 
the amount of circulation symptoms of dementia [49]. 
To our knowledge, another work has shown the ad-
dictive potential of donepezil and lovastatin combined 
therapy in a rat model where it was possible to induce 
an improvement in cognitive deficits [10].
There is indisputably a large variety of research 
on this subject. However, the question remains why 
according to some studies statins offer prospects and 
other studies dismiss them. Theoretically, blocking the 
amyloid cascade should translate into slowing down 
the dementia process. Many authors point out scientific 
errors in studies that show the relationship between 
statins and dementia. The testimony to this position is 
a large study involving 2,629 people showing a signifi-
cant effect of statin use on reducing the risk of AD. The 
duration of the study lasted 8 years, which may indicate 
that the effect of statins is obtained after a long time 
[45]. General studies on statins show that the strength 
of a substance is more important than its property, and 
the duration of action is important. In 2015, atorvastatin 
and rosuvastatin have been shown to be more effective 
[17]. Some researchers [40] accuse other studies of 
excluding people with lipid disorders from the studies, 
and these had a greater chance of obtaining positive 
effects of such therapy. It is worth remembering that 
each study model has its pros and cons. Different study 
results may be due to the fact that although most studies 
have included similar variables, some differences can 
be found that could potentially affect the final result. 
One of the disadvantages of the study: case-control 
study, unknown duration of statin use and no data on 
a specific type of medication, not taking into account 
comorbidities [17]. As other researchers note [35], the 
diversity of results may be due to limitations of prospec-
tive trials such as short observation time, short statin 
use time, lack of dementia type classification, lack of 
control of other vascular risk factors, or monitoring of 
statin compliance.
The contradictory results observed in the pub-
lished literature may partly result from differences in 
the examined patient populations in terms of basic 
cognitive functions and cholesterol levels, as well as 
the target endpoints of individual studies, which limits 
the proper interpretation of these important data [51]. 
There is a wide divergence among races regarding 
the risk of AD, the incidence of AD was higher among 
Latin and black women (2.29% and 2.11% respectively) 
than white. White men had the lowest incidence of AD 
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(1.23%), less than “other” women (1.37%) and men 
(1.29%). The incidence of AD was 1.86% and 1.94%, 
respectively in Latin and black men [42]. Clinical ma-
nipulations of statins to lower cholesterol to prevent 
and treat neurodegeneration have proved ineffective. It 
is postulated that the beneficial effect of statins may be 
due to their anti-inflammatory effect rather than lowering 
cholesterol [8], which makes sense especially since no 
correlation was found between the results of ADAS-cog 
and the concentration of total cholesterol or triglycerides 
[36]. The problem is that the tests detect only all cho-
lesterol, the free and esterified cholesterol [24].
Further research directions
To make any breakthrough in statin work, you need 
to focus your ambitions on a specific statin effect. An-
alyzing the overall work, you can think of two effects 
— the obvious reduction in cholesterol in the CNS and 
the fully understood pleiotropic effect on the expression 
of proapoptotic proteins. Research of the last decade, 
referring to problems with cholesterol balance and its 
deficiency leading to potential neurotoxicity, try to un-
derstand the pleiotropic effect at the cellular level and 
the results of such work must be admitted are at least 
promising. The authors of one of the works [52] devoted 
to the analysis of Van der Kent and colleagues’ results 
noted in the paper that inhibition of cholesterol synthesis 
and absence of interruptions of the isoprenoid pathway 
significantly reduces pTau levels. This in turn indicates 
that stored cholesterol esters in cells are responsible 
for the growth of pTau in human neurons, unlike what 
was thought to be the fault of other cholesterol synthe-
sis intermediates [24]. These studies have shown that 
although cholesterol esters themselves do not intensify 
the increase in pTau levels their decreased level in-
tensifies proteasomal activity, which in turn translates 
into pTau degradation [52]. Van der Kent et al. also 
confirm the cytotoxicity of statins and although they 
affect pTau degradation, the consequence of cholester-
ol-lowering and membrane integrity impairment leads 
to the destruction of astrocytes, which in the long run 
translates into further neurological defects. This theory 
would explain why, despite the observation of pTau 
protein reduction in other studies, no improvement was 
observed in the results of Adas-cog or MMSE [42]. Van 
der Kent finds a solution in the use of Efavirenz, which 
reduces cholesterol esters without a cytotoxic effect 
[24]. This suggests that although statins may not be 
solutions, they can be a hint for an appropriate Alz-
heimer treatment. Looking further at another aspect of 
statins, look at research conducted by YUNZI LI, which 
showed that in cell culture injected with Ab1-42 plaques, 
statins reduce caspase-3 levels, inhibit the release of 
cytochrome C from the mitochondria and increase the 
amount of Bcl antiapoptotic proteins 2/Bax relative to 
group Ab1-42 without statins. In the same study, SV 
significantly suppressed ROS accumulation at all three 
concentrations compared to the 10 µM Ab1-42 treat-
ment group. As the authors of this work emphasize, the 
mitochondrial pathway is the main pathway signaling 
apoptosis, and the substance that inhibits the process 
of apoptosis may prove to be crucial for stopping the 
progression of AD [53]. More evidence is provided in 
a 2016 study where, in a rat model, Iranian medical 
doctors proved that simvastatin induces the expression 
of the neuroprotective protein Klotho, which prevents 
oxidative stress by induction of MnSOD in hippocampal 
neurons. The same researchers showed that statins did 
not slow down the cognitive deficit, but they prevented 
the loss of reference memory [64]. Western blotting 
results have shown that statins reduce the concentration 
of miR-106b, which leads to apoptosis by increasing the 
expression of p53, Bax, caspase-3 and -9 [23].
Research in 2019 [54] aimed to show the rela-
tionship between the levels of Sestryn, Sirtuin  and 
statins. Researchers chose these proteins because of 
their potential neuroprotective mechanisms that could 
prevent amyloid beta-induced neurodegeneration. 
Sestrins (SESN2), whose expression is higher in cells 
with DNA damage or in response to Ab proteins. Their 
growth stimulates autophagy. Sirtuins are a group of 
deacetylases that regulate transcription and also have 
other functions, i.e. cell repair, suppression of inflam-
mation. The SIRT1 subgroup lowers Ab levels, reducing 
its production from APP. Atorvastatin has been found to 
enhance the expression of the SIRT1 protein. youth pro-
tein, which protects neurons [54]. Hence, this work [54] 
undertook to measure the level of this protein. Studies 
[54] noted that inhibition of atorvastatin in the growth of 
SESN2, which was induced by oxidative stress caused
by beta-amyloid, is indicative of the anti-inflammatory
effect of statins. In contrast, the increase in SIRT1 in-
duced by this statin indicates its neuroprotective effect. 
Of course, not all researches support the neuropro-
tective effect of statins [55], the cholesterol synthesis
enzyme DHCR24 (also called Seladin-1; Selective
Alzheimer’s Disease Indicator-1), which normally acts
neuroprotectively, is regulated in affected neurons [56]. 
By inhibiting caspase 3, Seladin-1 provides protection
against apoptosis and oxidative stress and preventing
its reduction may be crucial in therapy [55]. Among
the works highlighted by us, it is worth pointing out
that simvastatin regulates hippocampal cell apoptosis
by ATF-6 mediated ERK/AKT signaling pathway in the
CA1 region [57]. Another potential mechanism may be
activation of the phospho-MAPK/ERK pathway by lovas-
tatin, which reduces the neurotoxic effect of b-amyloid,
regardless of cholesterol [58]. It is also paying attention 
to the mutation of presenilin 1 protein (PS1). Research
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Figure 4. Further research directions [16, 24, 52–56] [no indication in the text]
by The Hopkins University in Baltimore shows the rela-
tionship between FAD-1 linked PS1 and aggregation of 
bamyloid. Also observed together with APP [13].
Conclusion 
It is known that Ab and vascular risk factors are 
involved in the pathogenesis of AD, but many aspects 
of AD pathogenesis are poorly understood [50]. There-
fore, it is too early to say that statins are ineffective in 
AD. Some researchers [36] hypothesize that if statins 
have a preventive or therapeutic effect, this would be 
more pronounced in people bearing the ApoE4 al-
lele and that statins would delay AD symptoms and 
progression. This indicates another aspect we have 
discussed - the selection of the right patient for ther-
apy. From the perspective of good therapy, various 
risk factors for AD need to be considered [12] such as 
hypertension. According to the researchers, the influ-
ence of factors such as atherosclerosis and CNS blood 
supply disorders can affect different patients to varying 
degrees. The right type of statin, for the right person, 
can be an inexpensive way to reduce AD  burden at 
the right time [42].
In 2018, the French Minister of Health decided that 
the drugs donepezil, galantamine, rivastigmine, and 
memantine were removed from the list and therefore 
would no longer be reimbursed by the national health 
insurance system [6]. That is why it is so important 
to reduce the occurrence of this disease by eliminat-
ing risk factors.  Perhaps if statins are not solution, 
researchers should not give up, because statins can 
provide more information about the pathophysiology of 
the disease and cognition will enable targeted therapy. 
What’s more, based on the statins of their metabolites, 
you can create substances that will be able to give pos-
itive influence to statins without their neurotoxic effect. 
Hence, our work states that there is a potential in statin 
therapy, but their impact should be fully understood 
so that they can be used in the prevention and treat-
ment of Alzheimer’s.
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